HROW Harrow Health Inc.

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually.

Harrow’s Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discussion on “Novel Treatments for Front-of-the-Eye Indications” at 1 p.m. Eastern time.

Both the and the will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit .

Contact:

Mike Biega, Vice President of Investor Relations and Communications



617-913-8890



EN
06/08/2025

Underlying

HROWHarrow Health Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow Announces Second-Quarter 2025 Financial Results

Harrow Announces Second-Quarter 2025 Financial Results Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quar...

August 11, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conferen...

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually. Harrow’s Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discuss...

August 6, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow To Report Second Quarter 2025 Financial Results After Market C...

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 12, 2025 NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, . Har...

July 29, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.90
VEC VECTRUS
SRPT Sarepta Therape... ... (+25)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

VEC VECTRUS
SRPT SAREPTA THERAPEUTICS INC.
SPR SPIRIT AEROSYSTEMS HOLDINGS INC. CLASS A
MNKD MANNKIND CORP.
BCRX BIOCRYST PHARMACEUTICALS INC.
ALNY ALNYLAM PHARMACEUTICALS INC
AGIO AGIOS PHARMACEUTICALS INC.
RY4C RYANAIR HOLDINGS PLC
LILA LIBERTY LATIN AMERICA A
DNLI DENALI THERAPEUTICS INC
ADT ADT INC
HROW HARROW HEALTH INC.
TWST TWIST BIOSCIENCE
DYN DYNE THERAPEUTICS
SMLP SUMMIT MIDSTREAM PARTNERS
RNA AVIDITY BIOSCIENCES
TNGX TANGO THERAPEUTICS INC
RYAN RYAN SPECIALTY GROUP HLDGS INC
RKLB ROCKET LAB USA INC
BTMD HAYMAKER ACQUISITION CORP III
IBRX IMMUNITYBIO INC
CDRO CODERE ONLINE LUXEMBOURG SA
XPOF XPONENTIAL FITNESS INC
UBXG U BX TECHNOLOGY LTD
FTLF FITLIFE BRANDS INC.
06/24/24 June 24, 2024 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
RF Regions Financi...
MSCI MSCI Inc. Class... ... (+33)

InsiderInsights Weekly Report: April 27, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

RF REGIONS FINANCIAL CORPORATION
MSCI MSCI INC. CLASS A
LGND LIGAND PHARMACEUTICALS INCORPORATED
CTRN CITI TRENDS INC.
BANC BANC OF CALIFORNIA INCORPORATED
LIND LINDBLAD EXPEDITIONS HOLDINGS
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
BRT BRT APARTMENTS
LOVE LOVESAC
FVCB FVCBANKCORP
HROW HARROW HEALTH INC.
INMB INMUNE BIO
MCFT INC.
CAPR MASTERCRAFT BOAT HOLDINGS
HQL CAPRICOR THERAPEUTICS
AUID TEKLA LIFE SCIENCES INVESTORS
BHVN IPSIDY INC.
MAIA BIOHAVEN LTD
MEGI MAIA BIOTECHNOLOGY INC
NPCT MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
RXO_w NUVEEN CORE PLUS IMPACT FD
ZURA RXO INC
ABEO ZURA BIO LTD
STCN ABEONA THERAPEUTICS INC.
KRRO STEEL CONNECT INC
EP KORRO BIO INC
ASGI EMPIRE PETROLEUM CORP
INTZ ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
EYPT INTRUSION INC
IZEA EYEPOINT PHARMACEUTICALS
INC.
IZEA WORLDWIDE INC
04/28/24 April 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch